Evidence map›Paper›PMID 41676603›Full record

ArticlebioRxiv : the preprint server for biology2026

Next generation protein-corrole bio-assemblies provide effective tumoricidal treatment in a metastatic triple-negative breast cancer model.

Vinay K Sharma, Nelyda Gonzalez-Almeyda, Simoun Mikhael, Ryan H Cho, Joseph Aceves, Kristin Ishaya, Sun Woo Kim, Abby Wiesenthal, Rebecca Benhaghnazar, Amirhesam Babajani and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Vinay K SharmaSchulich Faculty of Chemistry, Technion - Israel Institute of Technology, Haifa 32000, Israel.ORCID 0000-0002-2979-169X
Nelyda Gonzalez-AlmeydaDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Simoun MikhaelDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ryan H ChoDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Joseph AcevesDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Kristin IshayaDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sun Woo KimDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Abby WiesenthalDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Rebecca BenhaghnazarDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Amirhesam BabajaniDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ravinder AbrolDepartment of Chemistry and Biochemistry, California State University, Northridge, California 91330, United States.
Harry B GrayBeckman Institute, California Institute of Technology, Pasadena, California 91125, United States.
Zeev GrossSchulich Faculty of Chemistry, Technion - Israel Institute of Technology, Haifa 32000, Israel.ORCID 0000-0003-1170-2115
Lali Medina KauweDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-9807-5523

Funding

Targeting inhibitor-resistant breast tumors with HER3-homing nano-capsidsR01CA258204 · NCI · CEDARS-SINAI MEDICAL CENTER · PI LALI K MEDINA-KAUWE · 2022 to 2026
$1.9M
Nucleocapsid bioparticles eliciting multi-pronged attack on tumor metastasesR01CA270324 · NCI · CEDARS-SINAI MEDICAL CENTER · PI LALI K MEDINA-KAUWE · 2022 to 2026
$1.5M
NCI NIH HHS R01 CA258204NCI NIH HHS R01 CA270324
6 · The paper itself

Abstract

Assemblies that combine chemotherapeutics with tumor-targeting proteins are promising agents for treating resistant cancers but require full biochemical characterization before therapeutic deployment. We developed and optimized a HER3-targeting capsomere, HPK2.0, which forms stable nanoscale assemblies with cytotoxic corroles via electrostatic neutralization and shape complementarity. These nanocomplexes exhibit durable serum stability, HER3-dependent tumor invasion, and efficient endosomal escape, resulting in potent and selective cytotoxicity in triple-negative breast cancer (TNBC) cells. In an orthotopic metastatic TNBC model, systemic treatment with HPK2.0-corrole assemblies achieved 67-83% tumor regression, near-complete suppression of spontaneous lung metastasis, and a ~2-fold improvement in survival relative to mock treatment, with minimal off-target toxicity. By integrating tumor specificity with therapeutic potency, this next-generation protein-corrole platform establishes a clinically scalable strategy for treating metastatic HER3-positive TNBC.

Indexed as

HER3-targeted therapymetastatic cancernanotherapeuticsprotein–corrole assembliestriple-negative breast cancer

Identifiers

PMID41676603
PMCPMC12889662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.